ArticleFrontiers in genetics2011
A comparison of association methods for cytotoxicity mapping in pharmacogenomics.
Article in Frontiers in genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics.PloS one · 2025Article
- A Methodological Framework to Discover Pharmacogenomic Interactions Based on Random Forests.Genes · 2021Article
- Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.Journal of the American Chemical Society · 2019Article
- An investigation of gene-gene interactions in dose-response studies with Bayesian nonparametrics.BioData mining · 2015Article
- Identifying genes that mediate anthracyline toxicity in immune cells.Frontiers in pharmacology · 2015Article
- Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.Pharmacogenomics and personalized medicine · 2015Article
- Beyond ICJournal of pharmacogenomics & pharmacoproteomics · 2014Article
- Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.Pharmacogenomics · 2014Article
- Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Current molecular medicine · 2014Article
- Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Human molecular genetics · 2013Article
- Multivariate methods and software for association mapping in dose-response genome-wide association studies.BioData mining · 2012Article
- A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.Pharmacogenetics and genomics · 2012Article
- The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era.Human genetics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cytotoxicity assays of immortalized lymphoblastoid cell lines (LCLs) represent a promising new in vitro approach in pharmacogenomics research. However, previous studies employing LCLs in gene mapping have used simple association methods, which may not adequately capture the true differences in non-linear response profiles between genotypes. Two common approaches summarize each dose-response curve with either the IC50 or the slope parameter estimates from a hill slope fit and treat these estimates as the response in a linear model. The current study investigates these two methods, as well as four novel methods, and compares their power to detect differences between the response profiles of genotypes under a variety of different alternatives. The four novel methods include two methods that summarize each dose-response by its area under the curve, one method based off of an analysis of variance (ANOVA) design, and one method that compares hill slope fits for all individuals of each genotype. The power of each method was found to depend not only on the choice of alternative, but also on the choice for the set of dosages used in cytotoxicity measurements. The ANOVA-based method was found to be the most robust across alternatives and dosage sets for power in detecting differences between genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.